Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company Deals

Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal

Fineline Cube Oct 15, 2025

Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...

Company Deals

Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology

Fineline Cube Oct 15, 2025

On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...

Company Deals

Yanyin Tech and ChangJiang Pharma Partner to Advance AI in Drug Development

Fineline Cube Oct 15, 2025

China-based Yanyin Tech and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced on September 12, 2025,...

Drug

Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China

Fineline Cube Oct 15, 2025

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...

Company Drug

Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC

Fineline Cube Oct 15, 2025

Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...

Company Deals

Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies

Fineline Cube Oct 15, 2025

Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...

Company Deals Drug

Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine

Fineline Cube Oct 15, 2025

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...

Company Drug

Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease

Fineline Cube Oct 15, 2025

Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)...

Company Deals

GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio

Fineline Cube Oct 15, 2025

GenScript Biotech Corporation (HKG: 1548) today announced that its Contract‑Development‑and‑Manufacturing‑Organization (CDMO) platform, ProBio, received a...

Company Deals Drug

Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine

Fineline Cube Oct 15, 2025

Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...

Company Deals Drug

Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1

Fineline Cube Oct 15, 2025

Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results...

Company

Junshi Biosciences Reports 49 % YoY Revenue Growth in H1 2025, Raises Cash Reserves to RMB 3.49 B

Fineline Cube Oct 15, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its 2025 interim financial...

Company

Johnson & Johnson Reports Robust Q3 2025 Sales Growth, Boosts Full‑Year Outlook

Fineline Cube Oct 15, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced its third‑quarter results for 2025, showing a 5.4 %...

Company Deals

Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline

Fineline Cube Oct 15, 2025

Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a...

Company Deals Drug

Bio‑Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506

Fineline Cube Oct 15, 2025

Bio‑Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for...

Policy / Regulatory

National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand

Fineline Cube Oct 15, 2025

On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...

Company Drug

Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine

Fineline Cube Oct 15, 2025

Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...

Company Deals

Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia

Fineline Cube Oct 15, 2025

Shandong Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia Co., Ltd....

Company Deals

Zhaoke Ophthalmology Secures Exclusive Indonesian Distribution Deal for NVK002, a Novel Atropine‑Based Myopia Treatment

Fineline Cube Oct 15, 2025

Zhaoke Ophthalmology Limited (HKG: 6622), a leading China‑based ocular therapeutics company, announced today that it...

Company Drug

CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management

Fineline Cube Oct 14, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 107 108 109 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.